Yibin Yatai Biotechnology

Yibin Yatai Biotechnology is a clinical-stage biopharmaceutical company based in Yibin, China, dedicated to the discovery and development of novel small molecule therapeutics for cancer. The company primarily focuses on targeted oncology treatments, with a particular emphasis on the fibroblast growth factor receptor (FGFR) signaling pathway. Its lead clinical candidate, YT-101, is a highly selective FGFR inhibitor currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, including cholangiocarcinoma and urothelial carcinoma. Yibin Yatai leverages its regional R&D and manufacturing capabilities to advance its pipeline of precision medicines. The company aims to address significant unmet medical needs by providing more effective therapeutic options for patients with specific oncogenic mutations.